Special Issues

Special Issue Title: Complementary and Integrative Therapies for Women’s Health

· Print Special Issue Flyer

· Deadline for manuscript submissions:  31 October 2021  

Special Issue Editor

Guest Editor

Prof. Myeong Soo Lee, PhD

Clinical Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 34054, South Korea

Website | E-Mail1  | E-Mail2

Interests: Evidence-based Medicine; Clincal Practice Guideline; Menopause; Infertility

Associate Prof. Fan Qu

Department of Chinese Integrative Medicine, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, China

Website | E-Mail

Interests: Chinese Medicine; Clinical Trial; Infertility; Women’s Health; PCOS

Dr. Hye Won Lee

Herbal Medicine Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 34054, South Korea

Website | E-Mail

Interests: PCOS; Menopause; Infertility; Herbal Medicine

Special Issue Information

Dear Colleagues,

Due to social and economic changes, including population aging, birthrate declines, and increases in economic activity, the factors and countermeasures related to women’s health are changing rapidly. 
Women’s health is related to the health of future generations, not on the individual level, but on the social and economic levels, and realization of this has contributed to the concept of comprehensive women’s health management, which includes the social and environmental factors that affect females’ health.
Approaching women’s health issues efficiently necessitates changes in awareness, social culture, and medical information and systems as well as the professional approach to delivering health care throughout women’s lives.
One needed change is to treat not only pregnancy and childbirth, but also diseases specific to women and serious health problems that occur more frequently in women using an approach that considers the life cycle. Countermeasures should also integrate various medical technologies.
Endocrinologic diseases, including infertility, miscarriage, premenopausal syndrome, and polycystic ovary syndrome, are complicated processes controlled by endocrine regulation. Complementary and integrative therapies (CIT) has been used widely to treat women’s reproductive endocrinologic diseases, but CIT’s safety and effectiveness have not been fully evaluated. To close these gaps, the use of CIT to treat women’s reproductive endocrinologic diseases must be evaluated using scientific research methods.
In this special issue, we provide scientific evidence regarding the use of CIT to manage women’s health.
The potential topics include but are not limited to the following:
• The clinical efficacy of CIT for treating dysmenorrhea, women’s infertility, perimenopausal syndrome, polycystic ovary syndrome, etc.
• The mechanisms of CIT, including acupuncture, aromatherapy, herbal medicine, hypnosis, massage, meditation, and tai chi.
• The adverse effects and risks of using CIT to treat women’s reproductive endocrine disorders.

Prof. Myeong Soo Lee, Associate Prof. Fan Qu and Dr. Hye Won Lee

Guest Editors


Manuscript Submission Information

Manuscripts should be submitted online at https://ceog.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Clinical and Experimental Obstetrics & Gynecology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250. Submitted papers should be well formatted and use good English.


Women’s Health; Breast Cancer; Gynecology; Traditional Medicine; Complementary and Alternative Medicine; Integrative Medicine; Chinese Medicine

Share This Special Issue


Please wait a minute...
For Selected: Toggle Thumbnails
The effects of Chinese herbal medicine on the pregnancy outcomes of infertile women with polycystic ovary syndrome undergoing in vitro fertilization-embryo transfer: a systematic review and meta-analysis
Chang Liu, Minchen Dai, Lei Zhao, Fangfang Wang
Clinical and Experimental Obstetrics & Gynecology    2021, 48 (5): 1032-1043.   DOI: 10.31083/j.ceog4805166
Abstract113)   HTML22)    PDF(pc) (2419KB)(59)       Save

Background: At present, Chinese herbal medicine (CHM) has already been widely used as an important adjuvant treatment for polycystic ovary syndrome (PCOS) patients undergoing in vitro fertilization-embryo transfer (IVF-ET). This systematic review and meta-analysis were designed to evaluate the effects of CHM on the pregnancy outcomes of infertile women with PCOS undergoing IVF-ET. Methods: We searched seven electronic databases systematically for published articles to January 2021. All randomized controlled trials (RCTs) comparing CHM with blank or placebo for infertile PCOS patients undergoing IVF-ET were included. The measures of treatment effect were the pooled odds ratios (OR) of the clinical pregnancy rate, the abortion rate and the ovarian hyperstimulation syndrome (OHSS) incidence. Results: This meta-analysis included 10 studies involving 663 patients comparing CHM with blank or placebo for infertile PCOS patients undergoing IVF-ET. The pooled data showed that CHM could improve the clinical pregnancy rate (OR = 2.41, 95% CI: 1.73–3.35, p < 0.01) and reduce the OHSS incidence (OR = 0.31, 95% CI: 0.18–0.55, p < 0.01) of infertile PCOS patients with IVF-ET treatment. No significant difference in the abortion rate was found between the CHM and control groups (OR = 0.64, 95% CI: 0.23–1.81, p = 0.40). Discussion: CHM can be used as an auxiliary treatment for infertile PCOS patients undergoing IVF-ET.
Related Articles | Metrics

Current Issue

  • Volume 48, Issue 5